Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis

Inflammation Research

Volumn 58, Issue 2, 2009, Pages 109-117

  Anderson, G D ^a   Keys, K L ^a   De Ciechi, P A ^a   Masferrer, J L ^a  

^a PFIZER INC   (United States)

Author keywords

5 LOX; Animal models of RA; COX 1 2; Leukotriene; Prostaglandin

Indexed keywords

1 [3 [5 (4 FLUOROPHENOXY) 2 FURYL] 1 METHYL 2 PROPYNYL] 1 HYDROXYUREA; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; ANTIRHEUMATIC AGENT; CELECOXIB; COLLAGEN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DERACOXIB; DICLOFENAC; IBUPROFEN; ICOSANOID; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; PROSTAGLANDIN; SC 57416A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; ENZYME INHIBITION; FATTY ACID SYNTHESIS; INCIDENCE; MALE; MOUSE; NONHUMAN; RNA ANALYSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 5-LIPOXYGENASE; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; EPOXIDE HYDROLASES; HUMANS; HYDROXYUREA; LEUKOTRIENE B4; LEUKOTRIENES; MALE; MICE; MICE, INBRED DBA; PROSTAGLANDINS; PYRAZOLES; RNA, MESSENGER; SULFONAMIDES;

EID: 59049103619     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-009-8149-3     Document Type: Article

References (38)

1. Trentham D. Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum. 1982; 25: 911-6.
2. Phadke K FR, Parrish JE, Butler LD. Evaluation of the effects of various anti-arthritic drugs on type II collagen-induced mouse arthritis model. Immunopharmacology 1985; 10: 51-60.
3. Paska W MK, Croft M. Studies on type II collagen induced arthritis in mice. Agents Actions 1986; 3-4: 413-20.
4. Griswold DE HL, Meunier PC, DiMartino MJ, Hanna N. Effect of inhibitors of eicosanoid metabolism in murine collagen-induced arthritis. Arthritis Rheum. 1988; 31: 1406-12.
5. Smith SR PK, Bober LA, Kenworthy-Bott L, Phillips L, Pellerito F, da Fonseca M, Terminelli C. Inhibition of collagen II-induced arthritis in mice - a comparison of the effects of Sch 24937, immunosuppressants and nonsteroidal antiinflammatory drugs on the clinical expression of disease. Int J Immunopharmacol. 1990; 2: 165-73.
6. Bombardieri S CP, Ciabattoni G, Di Munno O, Pasero G, Patrono C, Pinca E, Pugliese F. The synovial prostaglandin system in chronic inflammatory arthritis: differential effects of steroidal and nonsteroidal anti-inflammatory drugs. Br J Pharmacol. 1981 Aug;73: 893-901.
7. Davies P BP, Goldenberg MM, Ford-Hutchinson AW. The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immunol. 1984; 2: 335-57.
8. Kojima F, Kato S, Kawai S. Prostaglandin E synthase in the pathophysiology of arthritis. Fundam Clin Pharmacol. 2005; 19: 255-261.
9. Kang RY F-MJ, Sigal E, Chu CQ. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol. 1996; 35: 711-8.
10. Baraf HSB. Efficacy of the Newest COX-2 Selective Inhibitors in Rheumatic Disease Current Pharmaceutical Design 2007; 13: 2228-36.
11. Ahmadzadeh N SM, Nobunaga M, Tawara T. Relationship between leukotriene B4 and immunological parameters in rheumatoid synovial fluids. Inflammation 1991; 15: 497-503
12. Weinblatt ME KJ, Coblyn JS, Helfgott S, Maier AL, Petrillo G, Henson B, Rubin P, Sperling R. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. J Rheumatol. 1992; 19: 1537-41.
13. Griffiths RJ, Smith M, Roach ML, Stock JL, Stam EJ, Milici AJ, et al. Collagen-induced Arthritis Is Reduced in 5-Lipoxygenase-activating Protein-deficient Mice. J Exp Med. 1997; 185, 1997: 1123-30.
14. Griffiths RJ, Pettipher ER, Koch K, Farrell CA, Breslow R, Conklyn MJ, et al. Leukotriene B4 Plays a Critical Role in the Progression of Collagen- Induced Arthritis. Proc Natl Acad Sci U S A. 1995; 92: 517-21.
15. Showell HJ, Conklyn MJ, Alpert R, Hingorani GP, Wright KF, Smith MA, et al. The Preclinical Pharmacological Profile of the Potent and Selective Leukotriene B4 Antagonist CP-195543. J Pharmacol Exp Ther. 1998; 285: 946-54.
16. Rao TS CJ, Shaffer AF, Isakson PC. Evaluation of 5-lipoxygenase inhibitors, zileuton, A-78773 and ICI-D-2138 in an ionophore (A-23187)-induced pleural inflammation model in the rat. Life Sci.1993; 53: 147-52.
17. Kachur JF, Askonas LJ, Villani-Price D, Ghoreishi-Haack N, Won-Kim S, Liang C-DD, et al. Pharmacological Characterization of SC-57461A (3-[Methyl[3-[4-(phenylmethyl)phenoxy]propyl]amin o]propanoic Acid HCl), a Potent and Selective Inhibitor of Leukotriene A4 Hydrolase II: In Vivo Studies. J Pharmacol Exp Ther. 2002; 300: 583-7.
18. Hegen M, Sun L, Uozumi N, Kume K, Goad ME, Nickerson-Nutter CL, et al. Cytosolic Phospholipase A2{alpha}-deficient Mice Are Resistant to Collagen-induced Arthritis. J Exp Med. 2003; 197: 1297-302.
19. Anderson GD, Banerjee S, Luthra HS, David CS. Role of Mls-1 locus and clonal deletion of T cells in susceptibility to collagen-induced arthritis in mice. J Immunol. 1991; 147: 1189-93.
20. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. 1993; 151: 6602-7.
21. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, et al. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J Med Chem. 1997; 40: 1347-65.
22. Millis DL WJ, Moyers T, Buonomo FC. Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs. Vet Ther. 2002; 3: 453-64.
23. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA. Selective Inhibition of Cyclooxygenase (COX)-2 Reverses Inflammation and Expression of COX-2 and Interleukin 6 in Rat Adjuvant Arthritis. J Clin Invest. 1996; 97: 2672-9.
24. Thornton S, Duwel LE, Boivin GP, Ma Y, Hirsch R. Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum. 1999; 42: 1109-18.
25. L Feng YX, G E Garcia, D Hwang, and C B Wilson. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest. 1995; 95: 1669-75.
26. Shiota N, Shimoura K, Okunishi H. Pathophysiological role of mast cells in collagen-induced arthritis: Study with a cysteinyl leukotriene receptor antagonist, montelukast. European Journal of Pharmacology 2006; 548: 158-66.
27. F.A. Wenger MK, M. Bisevac, C. Khodadayan, M. von Seebach, I. Schimke, H. Guski and J.M. Müller. Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters Clinical and Experimental Metastasis 2002; 19: 681-7.
28. Simon L. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med 1999; 106(5B): 37-42.
29. Brain SD, Williams TJ. Leukotrienes and inflammation. Pharmacology & Therapeutics 1990; 46: 57-66.
30. Chen M, Lam BK, Kanaoka Y, Nigrovic PA, Audoly LP, Austen KF, et al. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. 2006; 203: 837-42.
31. Peters-Golden M, Feyssa A. Transcellular eicosanoid synthesis in cocultures of alveolar epithelial cells and macrophages. Am J Physiol. 1993; 264: 438-47.
32. Nickerson-Nutter CL ME. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheum. 1996; 39: 515-21.
33. Myers LK, Kang AH, Postlethwaite AE, Rosloniec EF, Morham SG, Shlopov BV, Goorha S, Ballou LR.The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. 2000; 43: 2687-93.
34. Cannon GW MS, Cole BC, Griffiths MM, Radov LA, Ward JR. Effects of indomethacin, cyclosporin, cyclophosphamide, and placebo on collagen-induced arthritis of mice. Agents Actions. 1990; 29: 315-23.
35. Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory Resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004; 3: 401-16.
36. Zhang L ZX, Wu P, Li H, Jin S, Zhou X, Li Y, Ye D, Chen B, Wan J. BML-111, a lipoxin receptor agonist, modulates the immune response and reduces the severity of collagen-induced arthritis. Inflamm Res 2008; 57: 157-62.
37. Rioja I, Bush KA, Buckton JB, Dickson MC, Life PF. Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. Clin Exp Immunol. 2004; 137: 65-73.
38. Hom JT, Butler LD, Riedl PE, Bendele AM. The progression of the inflammation in established collagen-induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities. 1988; 18: 881-8.